Boehringer Ingelheim Auslandsbeteiligungs GmbH
Boehringer Ingelheim Auslandsbeteiligungs GmbH, a subsidiary of the globally renowned Boehringer Ingelheim, is headquartered in Germany and operates extensively across Europe, North America, and Asia. Founded in 1885, the company has established itself as a leader in the pharmaceutical and animal health industries, focusing on innovative research and development. With a diverse portfolio that includes prescription medicines, vaccines, and animal health products, Boehringer Ingelheim is committed to improving the quality of life for both humans and animals. Their unique approach to biopharmaceuticals and commitment to sustainability set them apart in a competitive market. The company has achieved significant milestones, including advancements in respiratory diseases and oncology, solidifying its position as a key player in the global healthcare landscape.
DitchCarbon Score
How does Boehringer Ingelheim Auslandsbeteiligungs GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim Auslandsbeteiligungs GmbH's score of 20 is lower than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim Auslandsbeteiligungs GmbH's reported carbon emissions
Boehringer Ingelheim Auslandsbeteiligungs GmbH currently does not have specific carbon emissions data available for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Boehringer Ingelheim, and any potential emissions data or climate commitments may be cascaded from its parent organisation. As of now, there are no documented reduction targets or climate pledges associated with Boehringer Ingelheim Auslandsbeteiligungs GmbH. This lack of specific initiatives suggests that the company may still be in the process of developing its climate strategy or aligning with broader corporate sustainability goals set by its parent company. In the context of the pharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and committing to science-based targets. However, without specific data or commitments from Boehringer Ingelheim Auslandsbeteiligungs GmbH, it is challenging to assess their current climate impact or future plans.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Boehringer Ingelheim Auslandsbeteiligungs GmbH is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
